The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...